menu

Performance

Paper

  1. Committee Approved Therapeutic Research
    S Shibui, Y Narita, J Mizusawa, et al.: Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). Cancer Chemother Pharmacol. 71: 511-521, 2013.
    T Wakabayashi , A Natsume, J Mizusawa, et al.: JCOG0911 INTEGRA study: a randomized screeing phase II trial of interferonβplus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma. J Neurooncol. 138: 627-636, 2018.
    T Kayama, S Sato, K Sakurada, et al.: Effect of surgery with salvage stereotactic radiosurgery versus surgery with whole-brain radiation therapy in patients with one to four brain metastases (JCOG0504): a phase III, noninferiority, randomized controlled trial. J Clin Oncol. 36:3282-3289, 2018.
  2. Therapeutic research with group representative management
    None
  3. Accompanying research, etc.
    None
    Other
  4. Review and commentary
    Kayama T: Therapeutic strategies for metastatic brain tumors. In: Yoshida J, Saito S, eds. Therapeutic Strategies and Outcomes in Neurosurgery – A Forward-Looking Survey 2003-2004. Igaku Shoin. 2005.
    Sato S, Kayama T: Clinical trials for metastatic brain tumors. Neurosurgery Bulletin. Neurosurgery Bulletin. 15: 937-942, 2005.
    Shibui S: New developments in the treatment of malignant brain tumors New developments in chemotherapy.
    Shibui S, Miyakita K, Onishi A, et al: Phase II/III study of ACNU versus ACNU+PCZ for astrocytoma grade3/4 (JCOG0305 clinical trial). Neuro-Oncology. 15: 50-53, 2005.
    Shibui S: Chemotherapy for malignant gliomas: Large-scale clinical trials and tailor-made therapy. Jpn J Neurosurg. 15: 3-9, 2006.
    Shibui S: New treatment for brain tumors. Annals of Medicine. Jpn J Neurosurg. 222: 953-954, 2007.
    Narita, Y., Shibui, S.: New movement of neurological diseases. Glioma. Journal of Neurosurgery. Journal of Neurosurgery. 25: 1242-1246, 2007.
    Nagane M: Chemotherapy of malignant glioma. No Shinkei Geka. 35: 433-450, 2007.
    Y Narita, S Shibui: Strategy of surgery and radiation therapy for brain metastases. Int J Clin Oncol. 14: 275-280, 2009.
    S Shibui: Treatment of metastatic brain tumors. Int J Clin Oncol. 14: 273-274, 2009.
    M Nagane: Recent progress in neuro-oncology. J Jpn S Clin Oncol. 46: 1344-1347, 2011.
    M Nagane: Recent progress in neuro-oncology. Jpn S Clin Oncol. J Clin Oncol. 68: 577-582, 2011.
    K. Miya, Y. Nakasu, S. Horiguchi, et al: Small fraction stereotactic radiotherapy: Indication, dose fractionation, and treatment outcome for metastatic brain tumor. Stereotactic Radiotherapy. Stereotactic Radiotherapy. 15: 1-6, 2011.
    Nagane M: Chemotherapy for glioma and primary malignant lymphoma of the central nervous system. Journal of the Kyorin Medical Society. 43(4): 151-168, 2012.
    Y Narita: Current knowledge and treatment strategies for grade II gliomas. Neurol Med Chir. 53(7): 429-437, 2013.
    M Nagane: Dose-dense temozolomide – Is it still promising? Neurol Med Chir (Tokyo). 55: 38-49, 2015. doi: 10.2176/nmc.ra.2014-0277, online December 20, 2014.
    Nakasu Y, Sanya K, Hayashi H, et al: VI Neoplastic diseases: metastatic brain tumors. J Neurological Syndromes (2nd edition), including other neurological diseases. 3: 445-449, 2014.
    Kinoshita M, Hashimoto N, Yoshimine T: Multifaceted treatment strategy for grade 2 glioma with long-term prognosis – the best treatment option at present. Neurosurgical Bulletin. Neurosurgery Bulletin. 25(10): 1083-1088, 2015.
    Nakasu Y: Multifaceted treatment strategy for malignant lymphoma with long-term prognosis: the best treatment option at present. Neurosurgical Bulletin. Neurosurgery Bulletin. 25(11): 1193-1204, 2015.
    Nakasu Y: Metastatic brain tumors. In “Neurosurgery,” edited by T. Ohta, revised and updated 12th edition. Kinbodo. 2: 1807-1825, 2016.
    Nakasu, Y.: Metastatic brain tumors. In EBM-Based Basic Treatment Guidelines for Neurological Diseases, edited by Tamura A et al. 4th ed. Medical View. Medical View. 210-216, 2016.
    Nakasu Y: New guidelines for metastatic brain tumors: significance in multidisciplinary treatment. Clinical oncology. 62(2): 49-54, 2016.
    Nakasu Y, Sanya K, Hayashi H: Brain tumor Update (11) Metastatic brain tumors. Neurosurgery. 44(10): 881-895, 2016.
    T. Ichikawa: BCNU wafers: chemotherapy for brain tumors. J Clin Oncol. 74(Suppl 7): 650-653, 2016.
    K. Mukasa: Decision making in the treatment of ependymal gliomas. Neurosurgical Practice. Bunko-do. Bunko-do. 59-63, 2016.
    Nagane M: Astrocytoma Tumors. In Neurosurgery II [12th revised edition]. In M. Nagane and T. Ohta (eds.). Kinbodo. 1463-1532, 2016.
    Nagane M: Malignant lymphoma. In EBM-based guideline for basic treatment of cerebral neurological diseases, 4th edition. Akira Tamura, Masao Matsutani, Teruo Shimizu, Sadaotoshi Tsuji, Yoshiaki Shiokawa, Yoshitaka Narita (eds). Medical View, Inc. 126-136, 2016.
    Nishikawa, R., Sugiyama, K., et al. Guidelines for the treatment of brain tumors, 2016 edition. In: Japanese Society of Brain Tumor Research (NPO). Kinbara Publishing Co. 2016.
    Hayashi H, Sanya K, Nakasu Y: Guidelines for the treatment of metastatic brain tumors. Neurosurgery Bulletin. Neurosurgery Bulletin. 27(1): 48-54, 2017.
    H Sasaki, K Yoshida: Treatment recommendations for adult patients with diffuse gliomas of grades IIand III according to the New WHO Classification in 2016. Neurologia Medico-Chirurgica (Tokyo) . 57(12):658-666, 2017. doi: 10.2176/nmc.ra.2017-0071. (2017 Aug 25 Epub)
    Nagane M: Central nervous system malignancies. Journal of the Japanese Society for Cancer Therapy (J Japan Soc Clin Oncol) 52 (1): 181-183, 2017.
    Nagane M: Development of therapy for malignant lymphoma of the central nervous system: multi-drug combination therapy and novel molecular targeted therapy. Latest Medicine 73 (11): 1441-1449, 2018.
    Kumabe T, Shibahara K, Saito R: Results of treatment of first-episode glioblastoma with intracerebroventricular carmustine (GIGLIADEL®). No Shinkei Geka, 46(5): 367-376, 2018.
    Nishikawa R, Sugiyama K, et al. Guidelines for the Treatment of Brain Tumors, 2nd Edition, 2019. 1. Adult Brain Tumors, 2. Pediatric Brain Tumors. Brain Tumor Society of Japan (NPO). Kinbara Publishing Co. 2019.
    M Nagane, Y Hayashi, A Shimizu, et al.: Safety and effectiveness of bevacizumab in Japanese patients with malignant glioma: a post-marketing Jpn J Clin Oncol in press.

Conference Presentations

  1. Committee approved therapeutic research
    S Shibui, T Kayama: A clinical trial for metastatic brain tumors in Japan (JCOG 0504). 17th Joint Congress of Asia & Pacific Federations & 53rd Annual Congress of the Japan Section. Jun 2006.
    S. Shibui, T. Kayama: Symposium Stereotactic radiotherapy for malignant gliomas. A Multicenter Trial for Malignant Glioma – Activities of JCOG Brain Tumor Group – The 15th Japanese Society for Stereotactic Radiotherapy. July 2006.
    Soichiro Shibui: Symposium 19: Prospects for new treatments for malignant brain tumors. Prospects of chemotherapy for malignant brain tumors. The 44th Annual Meeting of the Japanese Association for Cancer Therapy. October 2006.
    Soichiro Shibui: Multicenter clinical trial by JCOG Brain Tumor Group. The 24th Annual Meeting of the Japanese Society of Brain Tumors. October 2006.
    Kayama T: Prospects of SRS and SRT for metastatic brain tumors: A global standard protocol for the treatment of metastatic brain tumors. The 44th Annual Meeting of the Japanese Association for Cancer Therapy. October 2006.
    Shibui, S.: Results of a randomized phase II/III trial (JCOG 0305) for astrocytoma grade 3 and 4. The 25th Annual Meeting of the Japanese Society of Brain Tumors. December 2007.
    S Shibui: A clinical trial for metastatic brain tumors in Japan (JCOG 0504). 17th Joint Congress of Asia & Pacific Federations & 53rd Annual Congress of the Japan Section. Jun 2007.
    S Shibui: Clinical trials for malignant gliomas in Japan. 2007 Samsung International Brain Tumor Symposium. Sep 2007.
    S Shibui: A ranodmized controlled study for malignant gliomas by JCOG-Brain Tumor Study Group. 5th Meeting of The Asian Society for Neuro-oncology. 2007.
    S Shibui, JCOG-Brain Tumor Study Group: The result of a clinical trial for malignant gliomas by JCOG-Brain Tumors Study Group(JCOG0305).
    The 3rd Quadrennial Meeting of the World Federation of Neuro-oncolgy jointly with the 6th meeting of the Asian society for Neuro-Oncology. May 2009.
    S. Shibui, et al: Significance of central pathological diagnosis in a phase II clinical trial for grade 3/4 astrocytoma (JCOG0305). The 27th Annual Meeting of the Japanese Society for Brain Tumor Pathology. May 2009.
    Shibui S, et al: Results of a randomized phase II trial (JCOG 0305) for astrocytoma grade 3/4. The 68th Annual Meeting of the Japanese Neurosurgical Society. October 2009.
    Shibui, S., Kayama, T., Kumabe, T., et al: Final results of a randomized phase II trial (JCOG 0305) for grade 3/4 astrocytoma. The 27th Annual Meeting of the Japanese Society of Brain Tumors. November 2009.
    S Shibui, T Kayama, T Wakabayashi, et al.: Clinical trials for malignant brain tumors conducted by JCOG- Brain Tumor Study Group Clinical. The 15th Annual Scientific Meeting of the Society for Neuro-Oncology. Nov 2010.
    S Shibui, JCOG-Brain Tumor Study Group: Clinical trials conducted by JCOG-Brain Tumor Study Group. Oncology. May 2011.
    Y. Muragaki, T. Maruyama, T. Kumabe, et al: A randomized phase III study of temozolomide versus temozolomide in anaplastic glioma with prior ACNU recurrence (JCOG1016). The 73rd Annual Meeting of the Japanese Neurosurgical Society. 2014.
    Narita, Y., Miyakita, K., Eba, J., et al: JCOG Brain Tumor Group: A randomized phase III trial comparing irradiation alone and radiation therapy with temozolomide for diffuse astrocytoma with residual tumor (JCOG1303). The 73rd Annual Meeting of the Japanese Neurosurgical Society. 2014.
    Narita, Y., Shibui, S., Kayama, T., et al: Objectives and results of clinical research by the Brain Tumor Group of the Japanese Clinical Oncology Group (JCOG). The 35th Annual Meeting of the Japan Neurosurgical Congress. 2015.
    R Nishikawa: Neuro-Oncology in Japan. The 12th Asian Society for Neuro-Oncology. Sep 2015.
    R Nishikawa: JCOG summary. The 20th Japanese Society for the Surgery of Brain Tumors. Sep 2015.
    M. Nagane, K. Kobayashi, J. Mizusawa, et al: Dose-intensified temozolomide-bevacizumab sequential combination therapy for recurrent glioblastoma: a new multicenter randomized phase III trial JCOG1308. 74th Annual Meeting of the Japanese Neurosurgical Society. October 2015.
  2. Therapeutic research with group representative management
    Soichiro Shibui: EBM in the treatment of malignant brain tumors: Activities of the Japan Clinical Oncology Group (JCOG) Brain Tumor Study Group. The 62nd Annual Meeting of the Japanese Neurosurgical Society. Symposium-8: EBM in Neurosurgery from Japan. October 2003.
    Soichiro Shibui: Radiation therapy. 63rd Annual Meeting of the Japanese Cancer Association. Symposium 8. New treatment strategies for malignant brain tumors. September 2004.
    Soichiro Shibui, JCOG Brain Tumor Research Group: Multicenter trials for malignant brain tumors: Activities of the JCOG Brain Tumor Research Group. The 63rd Annual Meeting of the Japanese Neurosurgical Society. Symposium “Current Status and Future of Large-Scale Trials in Neurosurgery”. October 2004.
    Shibui, S., Asai, A., Kayama, T., et al: Randomized phase II/III multicenter trial of ACNU alone versus procarbazine plus ACNU for grade 34 astrocytoma. The 22nd Annual Meeting of the Japanese Society of Brain Tumors. October 2004.
    S Shibui: Randomized controlled trial on malignant gliomas by Japan Clinical Oncology Group-Brain Tumor Study Group (JCOG-BTSG). 3rd Meeting of the Asian Society for Neuro-Oncology. Nov 2004.
    Shibui S: Malignant brain tumors: Challenges of standardized therapy and resistance to therapy. Chemotherapy (Latest findings of standard treatment and tailor-made chemotherapy). The 25th Japan Neurosurgical Congress. May 2005.
    Kayama T: Significance and interpretation of standard medical care – from the standpoint of surgery. The 25th Japan Neurosurgical Congress. May 2005.
    S Shibui, The members of JCOG-Brain Tumor Study Group: Randomized controlled trial on malignant gliomas by JCOG-Brain Tumor Study Group (JCOG-BTSG). The 15th Annual Meeting of Korean Brain Tumor Society. Jul 2005.
    Shibui S: Evidence of chemotherapy for glioma: Based on the JCOG study. The 64th Annual Meeting of the Japanese Neurosurgical Society. Oct 2005.
    Kayama T: Standard of care for metastatic brain tumors: based on the JCOG study. The 64th Annual Meeting of the Japanese Neurosurgical Society. October 2005.
    Shibui S, JCOG Brain Tumor Study Group: Multicenter study of the JCOG Brain Tumor Study Group for malignant glioma. The 23rd Annual Meeting of the Japanese Society of Brain Tumors. October 2005.
    S Shibui, JCOG Brain Tumor Study group: Randomized controlled trial on malignant gliomas by JCOG-Brain Tumor Study Group (JCOG-BTSG). The 4th Meeting of the Asian Society for Neuro-Oncology. Nov 2005.
    Shibui, S., Miyakita, K., Onishi, A., et al: Phase II/III study of ACNU versus ACNU+PCZ for astrocytoma grade 3/4 (JCOG0305 clinical trial). The 30th Neurooncology Meeting. December 2005.
    S Shibui, The members of JCOG-BTSG: Randomized controlled trial on malignant gliomas by JCOG-Brain Tumor Study. 2006 International Brain Tumor Research and Therapy Meeting. Apr 2006.
    Soichiro Shibui: Symposium 19: Prospects for novel therapies for malignant brain tumors. Prospects of chemotherapy for malignant brain tumors. The 44th Annual Meeting of the Japanese Association for Cancer Therapy. Oct 2006.
    Soichiro Shibui: Chemotherapy for malignant glioma. The 25th Annual Meeting of the Japanese Society for Brain Tumor Pathology, April 2007.
    Soichiro Shibui: Standard of treatment for malignant glioma. The 27th Annual Meeting of the Japanese Neurosurgical Congress. May 2007.
    T Wakabayashi, A Natsume, M Fujii, et al: Interim report of combination therapy with interferon-beta and temozolomide for malignant glioma (Integra study). XIV world congress of neurological surgery.
    S Shibui: The result of a clinical trial for malignant gliomas by JCOG-Brain Tumors Study Group. XIV World Congress of Neuro- surgery of The World World Congress of Neuro- surgery of The World Federation of Neurosurgical Societies.
    Wakabayashi T, Shibui S, et al: Clinical trials in Japan for the standard treatment of malignant gliomas. The 47th Annual Meeting of the Japanese Association for Cancer Therapy. Oct 2009.
    T Wakabayashi: Present and future of management of glioma. 58th annual conference of neurological society of India.
    T Wakabayashi: Mulitomodal treatment strategy for glioma.
    T Wakabayashi, S Shibui: Randomized phase II study of IFN-b plus Temodar chemoradiation for primary glioblastoma (JCOG0911:INTEGRA phase II study). The 69th Annual Meeting of the Japanese Neurosurgical Society. October 2010.
    Wakabayashi T: The role of INTEGRA study in the treatment strategy of malignant brain tumors. The 29th Annual Meeting of the Japanese Society for Brain Tumor Pathology. May 2011.
    M. Nagane: JCOG Brain Tumor Group (Special Seminar): Standard treatment for glioma and multicenter clinical trial by JCOG Brain Tumor Group. The 72nd Annual Meeting of the Japanese Neurosurgical Society. October 2013.
    M Nagane: Update on JCOG1114 for newly diagnosed PCNSL in Japan. 2017 International PCNSL Collaborative Group Meeting, American Society of Hematology. Dec 2017.
    M Nagane: Clinical trials for gliomas and primary central nervous system lymphoma in Japan by JCOG Brain Tumor Study Group. The 15th Meeting of the Asian The 15th Meeting of the Asian Society for Neuro-Oncology. Oct 2018.
  3. Incidental research, etc.
    Other
  4. Review and commentary
    M. Nagane: JSCO University 2011. -Central Nervous System Tumor- Year in Review: Japan. 49th Annual Meeting of the Japanese Society for Cancer Therapy. October 2011.
    M. Nagane: Treatment strategy for malignant glioma and PCNSL. 71st Annual Meeting of the Japanese Neurosurgical Society. Oct 2012.
    M. Nagane: Standard treatment of glioma and multicenter clinical trials. The 32nd Annual Meeting of the Japanese Society for Brain Tumor Pathology. May 2014.
    Y. Sonoda, Y. Sato, R. Saito, et al: Safety and therapeutic efficacy of implantation of gliadel: a collaborative study in Yamagata, Kitasato, and Tohoku University. The 20th Annual Meeting of the Surgical Society for Brain Tumors. September 2015.
    Nakasu Y, Sanya K, Hayashi H: New guidelines for metastatic brain tumors: implications for multidisciplinary treatment. The 53rd Annual Meeting of the Japanese Association for Cancer Therapy. October 2015.
    Tomotsugu Ichikawa: Current status and prospect of glioma treatment (special lecture). Meet the Expert in Iwakuni. Dec 2015.
    Y. Nakasu: Metastatic brain tumors: new guidelines and multidisciplinary treatment. The 36th Congress of Neurosurgery in Japan. May 2016.
    Sonoda Y, Kumabe T, Tominaga T, et al: Outcomes of indwelling carmustine in malignant glioma: a backward-looking multicenter study at seven centers in Japan. The 21st Annual Meeting of the Japanese Society for Surgery of Brain Tumors. September 2016.
    Sonoda, Y., Shibahara, K., Matsuda, K., et al: Outcomes of indwelling carmustine in malignant glioma: A retrospective multicenter study at seven centers in Japan. The 75th Annual Meeting of the Society of Neurosurgery. September 2016.
    Y Nakasu: Brain Metastases: Treatment options and relevant outcome measures:Surgery. European Society for Medical Oncology Asia 2016 Congress. 2016.
    Y Nakasu: Brain Metastases: Treatment options and relevant outcome measures: Surgery. The 37th Annual Meeting of the Japanese Neurosurgical Congress. May 2017.
    Sanya K, Nakasu Y, Hayashi H: Central Nervous System Metastases of Cancer “Treatment of Metastatic Brain Tumors”. The 37th Annual Meeting of the Japanese Neurosurgical Congress. May 2017.
    Tanaka Shota: Genetic abnormalities and revised WHO classification of gliomas. 36th Japanese Society for Brain Tumor Pathology Educational Seminar. 2018 Jun.
    M. Nagane: Therapeutic development for malignant brain tumors: past and future perspectives. The 36th Annual Meeting of the Japanese Society for Brain Tumor Pathology. Sep. 2018.